WHAT IS THE AIM OF THE REGULATION?
- Regulation (EU) 2017/746 updates the rules on placing on the European Union (EU) market, making available and putting into service in vitro diagnostic (IVD) medical devices1 for human use and their accessories.
- It also contains rules on the conduct of performance studies2 for IVD medical devices or accessories.
- It aims to improve patient safety by introducing stricter procedures for conformity assessment (to ensure that unsafe or non-compliant devices do not end up on the market) and post-market surveillance.
KEY POINTS
Scope
The regulation covers IVD medical devices for human use and their accessories (hereafter referred to as devices). However, devices manufactured and used in the same healthcare institution are exempted from the rules, other than those relating to the relevant general safety and performance requirements, so long as a number of conditions are fulfilled.
Classification system
The classification system for the devices has been adapted to the rapid scientific progress in the field and to the international guidance. Devices are classified according to their intended purpose and their inherent risks (classes A, B, C and D – for more details, see Annex VIII to the regulation).
Harmonised standards and common specifications
- An implementing act adopted by the European Commission – Implementing Decision (EU) 2021/1195, as amended – lists the harmonised standards drafted in support of Regulation (EU) 2017/746.
- Implementing Regulation (EU) 2022/1107 lays down common specifications on the performance of certain class D devices. The manufacturers must follow the specifications or show that their alternative solution is at least equivalent in terms of the safety and performance of the device.
Notified bodies
- The regulation tightens the rules concerning how the independent notified bodies, which assess the conformity of medium- and high-risk devices before they are placed on the market, are designated, organised and monitored.
- These bodies have to meet the same high quality standards throughout the EU and must have the required staff to successfully perform their conformity assessment tasks.
- On-site inspections of manufacturers, of which some visits are unannounced, must be carried out.
- Implementing Regulation (EU) 2017/2185 sets out the list of codes and corresponding types of devices for the purpose of specifying the scope of the designation as notified bodies in the field of IVDs.
- Implementing Regulation (EU) 2026/977 lays down certain uniform quality management and procedural requirements for the conformity assessment activities carried out by notified bodies.
Performance studies
- The manufacturer must support its claims on the performance of the device with rigorous evidence, including scientific validity and analytical and clinical performance data.
- The regulation specifies what is required in the data collection of high-risk performance studies on devices.
- Performance studies conducted in more than one EU Member State will be subject to a coordinated assessment. Under Regulation (EU) 2024/1860, the procedure will:
- initially apply only in participating Member States; and
- become mandatory for all Member States five years after the Commission publishes a notice confirming that the relevant electronic system is functional.
Manufacturers’ obligations
- Manufacturers:
- have clearer and more stringent obligations to monitor the quality, performance and safety of devices;
- are required to have measures in place that correspond to the level of risk, type of device and size of the company;
- must ensure they have sufficient financial coverage with respect to their potential liability under the Product Liability Directive (see summary), along with quality management and post-market surveillance systems.
- In the event of damages due to defective devices, a manufacturer’s authorised representative is jointly and severally liable.
- Since 10 January 2025, if it is reasonably foreseeable that an interruption or discontinuation of supply could result in serious harm or a risk of serious harm to patients or public health, manufacturers must, except in exceptional circumstances:
- inform the relevant competent authority and the economic operators, health institutions and healthcare professionals they supply directly at least six months in advance; and
- state the reasons in the information given to the competent authority.
Economic operators that receive the information must pass it on without undue delay to those they supply directly. These obligations also apply to devices covered by the transitional provisions.
Traceability
- A system of unique device identifiers (UDIs) for registering devices and manufacturers, importers and authorised representatives ensures the traceability of devices throughout the supply chain and that, should problems arise, measures can be taken rapidly.
- Implementing Decision (EU) 2019/939 lists the issuing entities designated to operate a system for the assignment of UDIs in the field of medical devices. The designation was renewed by Implementing Decision (EU) 2024/2120.
High-risk devices
- In the event of the first certification for a new class D device, for which common specifications are not available, an expert panel will provide its views on the performance of the device. Although the notified body is not bound by the panel’s opinion, it has to provide a justification for not following it.
- The Commission may designate EU reference laboratories that will test whether class D devices perform as claimed by the manufacturer. Implementing Regulation (EU) 2023/2713 designated the first EU reference laboratories for certain class D devices. The notified body may not deliver the certificate for the device if the scientific opinion of the EU reference laboratory is negative.
- The tasks of and criteria for the EU reference laboratories in the field of IVDs are set out in Implementing Regulation (EU) 2022/944.
- Implementing Regulation (EU) 2022/945 sets out the rules on fees that may be levied by the EU reference laboratories in the field of IVDs.
Genetic counselling
Patients tested with a genetic test must be provided with all relevant information on its nature, significance and implications. They must be given appropriate access to counselling in cases where a test provides information on the genetic predisposition for medical conditions and/or diseases that are generally considered to be untreatable.
Incident reporting
In addition to the obligation for manufacturers to report serious incidents (resulting in death or a serious deterioration in a person’s health) and trends in non-serious incidents (e.g. side effects from the use of a device), the regulation introduces the obligation for Member States to encourage and enable healthcare professionals, users and patients to report suspected incidents at the national level.
Market surveillance
The relevant authorities in the Member States are responsible for checking that devices on their market comply with the regulation and do not endanger the health or safety of patients, users or other people.
European database on medical devices
- A centralised database, called the European database on medical devices (Eudamed), is being gradually rolled out to provide Member States, businesses, patients, healthcare professionals and the public with information on medical devices available in the EU.
- Implementing Regulation (EU) 2021/2078 sets out the arrangements necessary for Eudamed’s set-up and maintenance.
- Under Regulation (EU) 2024/1860, the obligations and requirements linked to an individual electronic system generally apply six months after the Commission publishes a notice confirming that it is functional.
- Since 28 May 2026, the following Eudamed modules have been mandatory:
- The remaining systems will become mandatory following separate Commission notices.
Transition periods
Due to the challenges to ensuring proper implementation and application presented by the COVID‑19 pandemic, Regulation (EU) 2017/746 was amended by Regulation (EU) 2022/112 and subsequently by Regulation (EU) 2024/1860, which further extended some transition periods, as follows:
- devices covered by a certificate issued by a notified body under Directive 98/79/EC that remains valid under the transitional rules: 31 December 2027;
- devices covered by a declaration of conformity drawn up by the manufacturer under Directive 98/79/EC, which newly require the involvement of a notified body:
- class D: 31 December 2027,
- class C: 31 December 2028,
- class B and class A sterile: 31 December 2029.
These extensions apply only if certain conditions are met, including continued compliance with Directive 98/79/EC, no significant changes in design or intended purpose, no unacceptable risk and the taking of the required steps towards compliance with Regulation (EU) 2017/746.
Regulation (EU) 2023/607 removed the former time limit for devices already in the supply chain. Devices lawfully placed on the market under Directive 98/79/EC or during the applicable transitional period may continue to be made available on the market or put into service.
Most requirements applicable to devices manufactured and used within the same health institution have applied since 26 May 2024. The requirement to justify that the needs of the patients cannot be met by an equivalent device on the market applies from 31 December 2030.
Implementing acts
The full list of implementing acts to Regulation (EU) 2017/746 can be found here.
Repeal
Regulation (EU) 2017/746 repeals Directive 98/79/EC as of 26 May 2022, although some of its rules continue to apply during the transition to the new system.
Decision 2010/227/EU will be repealed in accordance with the timetable for Eudamed.
FROM WHEN DOES THE REGULATION APPLY?
The regulation has applied since 26 May 2022.
Its rules on anticipated interruptions to or discontinuations of supply have applied since 10 January 2025.
BACKGROUND
- This regulation is one of two adopted by the EU to overhaul its laws on medical devices. The second regulation (Regulation (EU) 2017/745 – see summary) concerns medical devices.
- For further information, see:
KEY TERMS
- In vitro diagnostic medical devices. Term covering a wide variety of devices used to provide information on (a) a physiological or pathological process or state; (b) a congenital physical or mental impairment; (c) the predisposition to a medical condition or disease; (d) the safety and compatibility between the materials used and the specimens of the body intended to be used; (e) treatment response or reactions; (f) defining or monitoring therapeutic measures. Examples range from self-tests for pregnancy to tests for highly transmissible agents using specimens taken from the human body.
- Performance studies. Studies that establish or confirm the analytical or clinical performance of a device.
MAIN DOCUMENTS
Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU (OJ L 117, 5.5.2017, pp. 176–332).
Successive amendments to Regulation (EU) 2017/746 have been incorporated into the original text. This consolidated version is of documentary value only.
RELATED DOCUMENTS
Implementing Decision (EU) 2021/1195 on the harmonised standards for in vitro diagnostic medical devices drafted in support of Regulation (EU) 2017/746.
See consolidated version.
Regulation (EU) 2017/745 on medical devices.
See consolidated version.
Decision 2010/227/EU on the European Databank on Medical Devices (Eudamed).